98%
921
2 minutes
20
Bariatric surgery is a widely used treatment for morbid obesity, but it can lead to neurological complications, including Guillain-Barré Syndrome (GBS), a rare immune-mediated polyneuropathy. The mechanisms underlying post-bariatric GBS remain unclear, and no comprehensive review has evaluated its incidence, risk factors, and outcomes. This systematic review synthesizes available clinical data to assess the relationship between bariatric surgery and GBS, focusing on its presentation, diagnosis, and management. A systematic literature search was conducted in Web of Science, PubMed, and Scopus following PRISMA guidelines. Studies reporting GBS following bariatric surgery were included. Data extraction focused on demographics, clinical presentation, laboratory findings, treatment approaches, and outcomes. Study quality was assessed using the Joanna Briggs Institute (JBI) tool. GBS cases were predominantly reported in female patients, with symptom onset occurring within weeks to months post-surgery. The most common clinical features included ascending motor weakness, sensory disturbances, hyporeflexia, and autonomic dysfunction. Laboratory findings showed elevated cerebrospinal fluid protein and abnormal nerve conduction studies. Patients were treated with intravenous immunoglobulin (IVIG), plasmapheresis, and nutritional supplementation, particularly thiamine and vitamin B12. Recovery varied; some patients regained full function, while others experienced persistent neurological deficits or severe complications such as respiratory failure. GBS is a rare but serious post-operative complication of bariatric surgery, potentially linked to immune dysregulation and nutritional deficiencies. Early recognition and prompt intervention are critical. Further research is needed to clarify underlying mechanisms, optimize treatment, and improve preventive strategies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s11695-025-08192-x | DOI Listing |
Diabetes Res Clin Pract
September 2025
Department of Intensive Care Medicine, Chi Mei Medical Center, Tainan, Taiwan; School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan. Electronic address:
Obes Surg
September 2025
Department of Nephrology, Xinqiao Hospital, Army Medical University, Chongqing, China.
Obes Surg
September 2025
Department of Medical and Surgical Sciences, Internal Medicine Unit, Columbus-Gemelli Hospital, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Obesity is a globally prevalent condition associated with elevated morbidity and mortality. Metabolic and bariatric surgery offers a definitive treatment for class III (BMI > 40) obesity, achieving substantial, enduring weight loss and improving metabolic health. Despite extensive research on the physical benefits, comparatively fewer reviews investigate the psychosocial and relational changes accompanying these procedures.
View Article and Find Full Text PDFObes Surg
September 2025
Department of Minimally Invasive Digestive Surgery, Antoine Béclère Hospital, AP-HP, 157 Rue de La Porte de Trivaux, 92141 Clamart, Clamart, France.
Background: Bariatric surgery (BS) is the most effective treatment for severe obesity, but a significant proportion of patients experience insufficient weight loss (IWL) or weight regain. Glucagon-like peptide-1 receptor agonists (arGLP-1) have emerged as a promising adjunctive therapy for managing these suboptimal outcomes. This study evaluates the efficacy and safety of arGLP-1 in patients with IWL or WR after BS.
View Article and Find Full Text PDFJ Arthroplasty
September 2025
Virginia Commonwealth University Health System, Department of Orthopaedic Surgery, 1200 E Broad St, Richmond, VA, 23298, USA.
Introduction: Obesity is an increasingly prevalent comorbidity that confers greater risks of postoperative complications following total joint arthroplasty, underscoring the need for viable preoperative weight loss. The objective of this study was to compare the risk of 90-day adverse events in patients undergoing total knee arthroplasty (TKA) following bariatric surgery versus treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RA).
Methods: A retrospective review of a national research network from May 1, 2005, to February 12, 2025, identified patients undergoing TKA with bariatric surgery or GLP-1 RA prescriptions in the 18 months preceding their joint arthroplasty.